Anavex Life Sciences Corp.

NASDAQ: AVXL · Healthcare · Biotechnology

PublicHQ New York City, NY · New YorkCIK 0001314052Reports USD

#1 of 1,418 Healthcare companies by revenue

EA Score

——

FH 61DQ —GM —SS 65

v0.1 · 35/100 weight · pillars only

↑ balance-sheet leverage, Altman-Z · ↓ Piotroski F, workforce scale

Methodology →

Revenue TTM

Rev growth YoY (TTM)

needs 8 qtrs

Net income (FY)

-$46.4M

Employees

as of 2026-08-13

Market cap

$316.0M

as of 2026-08-13

Financials — latest annual

SEC EDGAR · USD-normalized

ConceptUSDNativeFY

Net income-$46.4M-$46.4M2025

Operating income-$51.4M-$51.4M2025

Total assets$103.8M$103.8M2025

Liabilities$8.9M$8.9M2025

Equity$94.9M$94.9M2025

Revenue by segment

No segmentation disclosed for this filer. n/a

The read

What is Anavex Life Sciences Corp.’s financial profile?

Anavex Life Sciences Corp. earned -$46.4M in FY2025 net income.

Peers · Healthcare

Mobia Medical, Inc. Common Stock——Scribe Therapeutics Inc.——Neumora Therapeutics, Inc. Common Stock——Turn Therapeutics Inc.——Alamar Biosciences, Inc.——Aurora Cannabis Inc.——

Neighbors

New York →

JPMorgan Chase & Co.$182.4B72B Morgan Stanley$34.3B61C The Goldman Sachs Group, Inc.——Philip Morris International Inc.$40.6B86A American Express Company$41.3B78B+Citigroup Inc.$85.2B55C

Key facts

CEOTerrie Kellmeyer

SectorHealthcare

IndustryBiotechnology

HeadquartersNew York City, NY

ExchangeNASDAQ: AVXL

Employees34

IPO date2006-08-02

Latest filings

10-Q2026-08-28 10-Q2026-08-28 8-K2026-08-25 8-K2026-08-17 8-K2026-08-11 8-K2026-08-03 8-K2026-07-30 8-K2026-07-20

Financials: SEC EDGAR (XBRL), USD-normalized per IAS 21 · TTM/quarterly + segments: FMP from filed disclosures · Filings: EDGAR submissions. County headcount and EA Score are in progress — see docs/DATA_GAPS.md.